Study S001332

Repositioning Omega-3 Fatty Acids For Treatment Of Glycaemia And Cardiometabolic Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07677995
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: SINGLE
Status: ENROLLING_BY_INVITATION
Enrollment: 60
Start: 2026-09
Primary completion: 2026-12
Lead sponsor: University of Ulster
Conditions: Type 2 Diabetes; Cardiovascular Disease; Omega-3 Fatty Acids
Interventions: DIETARY_SUPPLEMENT:Omega-3 Fatty Acids; DRUG:Semaglutide 0.25 mg; DIETARY_SUPPLEMENT:Placebo
Results posted: FALSE
Secondary identifiers: OTHER_GRANT:TA/PPA/25/215037

Registered primary outcomes

To evaluate the change in fasting glucose from baseline after 28 days of treatment, compared to each treatment group and placebo. [From baseline to 28 days of treatment]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.